151 related articles for article (PubMed ID: 12208487)
1. Effects of various fibrates on serum alkaline phosphatase activity.
Ganotakis E; Tsimihodimos V; Bairaktari E; Rizos E; Athyros V; Seferiades C; Elisaf M
Atherosclerosis; 2002 Nov; 165(1):187-8. PubMed ID: 12208487
[No Abstract] [Full Text] [Related]
2. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
Farnier M; Salko T; Isaacsohn JL; Troendle AJ; Dejager S; Gonasun L
Am J Cardiol; 2003 Oct; 92(7):794-7. PubMed ID: 14516878
[TBL] [Abstract][Full Text] [Related]
3. Abnormal lipid profiles on fibrate derivatives.
McLeod AJ; Warren RJ; Armitage M
Lancet; 1996 Jan; 347(8996):261. PubMed ID: 8551900
[No Abstract] [Full Text] [Related]
4. Fibrate-induced increase in blood urea and creatinine.
Lipscombe J; Bargman JM
Nephrol Dial Transplant; 2001 Jul; 16(7):1515. PubMed ID: 11427661
[No Abstract] [Full Text] [Related]
5. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.
Abourbih S; Filion KB; Joseph L; Schiffrin EL; Rinfret S; Poirier P; Pilote L; Genest J; Eisenberg MJ
Am J Med; 2009 Oct; 122(10):962.e1-8. PubMed ID: 19698935
[TBL] [Abstract][Full Text] [Related]
6. Statin-fibrate combinations in patients with combined hyperlipedemia.
Athyros VG; Papageorgiou AA; Kontopoulos AG
Atherosclerosis; 2001 Mar; 155(1):263-4. PubMed ID: 11293392
[No Abstract] [Full Text] [Related]
7. Lipid profiles on fibric-acid derivatives.
Capps NE
Lancet; 1994 Sep; 344(8923):684-5. PubMed ID: 7915370
[No Abstract] [Full Text] [Related]
8. Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia.
Dick TB; Marples J; Ledermann HM; Whittington J
Curr Med Res Opin; 1981; 7(8):489-502. PubMed ID: 7030635
[No Abstract] [Full Text] [Related]
9. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
Broeders N; Knoop C; Antoine M; Tielemans C; Abramowicz D
Nephrol Dial Transplant; 2000 Dec; 15(12):1993-9. PubMed ID: 11096145
[TBL] [Abstract][Full Text] [Related]
10. The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
Schonfeld G
Atherosclerosis; 1994 Dec; 111(2):161-74. PubMed ID: 7718018
[TBL] [Abstract][Full Text] [Related]
11. Drug interactions with fibric acids.
Lozada A; Dujovne CA
Pharmacol Ther; 1994 Aug; 63(2):163-76. PubMed ID: 7809177
[TBL] [Abstract][Full Text] [Related]
12. Ciprofibrate and lipid profile.
Chandler HA; Batchelor AJ
Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
[No Abstract] [Full Text] [Related]
13. Effect of ciprofibrate on C-reactive protein and fibrinogen levels.
Rizos E; Kostoula A; Elisaf M; Mikhailidis DP
Angiology; 2002; 53(3):273-7. PubMed ID: 12025914
[TBL] [Abstract][Full Text] [Related]
14. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Mikhailidis DP; Jagroon IA
Metabolism; 2001 Nov; 50(11):1385-6. PubMed ID: 11715936
[No Abstract] [Full Text] [Related]
15. Fibrate treatment can increase serum creatinine levels.
Tsimihodimos V; Kakafika A; Elisaf M
Nephrol Dial Transplant; 2001 Jun; 16(6):1301. PubMed ID: 11390746
[No Abstract] [Full Text] [Related]
16. [Does hypothyroidism potentialize muscular toxicity of fibrates?].
Harlé JR; Toussirot E; Disdier P; Drancourt M; Weiller PJ
Rev Med Interne; 1990; 11(4):336. PubMed ID: 2096444
[No Abstract] [Full Text] [Related]
17. Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
Maiguma T; Fujisaki K; Itoh Y; Makino K; Teshima D; Takahashi-Yanaga F; Sasaguri T; Oishi R
Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):289-96. PubMed ID: 12644902
[TBL] [Abstract][Full Text] [Related]
18. Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography.
Masnatta LD; Cuniberti LA; Rey RH; Werba JP
J Chromatogr B Biomed Appl; 1996 Dec; 687(2):437-42. PubMed ID: 9017468
[TBL] [Abstract][Full Text] [Related]
19. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.
Rizzo M; Berneis K
Curr Med Res Opin; 2007 May; 23(5):1103-11. PubMed ID: 17519077
[TBL] [Abstract][Full Text] [Related]
20. Effects of clofibric acid and bezafibrate administration on activities of alkaline phosphatase and other enzymes in livers of rats.
Walli AK; Seidel D
Res Exp Med (Berl); 1981; 179(2):153-61. PubMed ID: 7280363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
